Meta-analysis publish date | Which Meta-analysis (or meta-analyses) included this study | Individual study publish date | Citation | Study design | Patient population | Total (n) | Observation arm description | Comparator arm description | Interventions | Event(s) | Event count in observation arm | Total (n) in observation arm | Percent incidence of Events in observation arm (in decimal form) | Event count in comparator arm | Total (n) in comparator arm | Percent incidence of Events in comparator arm (in decimal form) | Total number of Events | Measurement type | Meaurement value | Statistitical measurement type | Statistitical measurement value | Statistitical measurement value | Statistitical measurement value | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tuesday, March 26, 2013 Friday, June 22, 2018; Wednesday, June 13, 2012; Saturday, February 25, 2017; Monday, June 5, 2017 | PMID: 23529007; 29932297; 22676194; 28367249; 28585035 | Tuesday, July 13, 2010 | PMID: 20628391 | multicenter, prospective, randomized phase 3 study | metastatic colorectal cancer patients | 149 | (UGT1A9*22/*1, *22/*22), UGT1A7*3/*3, *2/*3, *2/*2, *1/*3, *1/*2) | UGT1A1*28/*28, UGT1A1*1/*28 | FOLFIRI (biweekly irinotecan (180 mg m-2) + 5FU/LV OR FUIRI (weekly irinotecan 80 mg m-2) + 5FU/LV | Neutropenia | - | - | 46 | 216 | 0.21 | 23 | 93 | 0.25 | 69 | ||||||||
PMID: 20628391 | multicenter, prospective, randomized phase 3 study | metastatic colorectal cancer patients | 149 | (UGT1A9*22/*1, *22/*22), UGT1A7*3/*3, *2/*3, *2/*2, *1/*3, *1/*2) | UGT1A1*28/*28, UGT1A1*1/*28 | FOLFIRI (biweekly irinotecan (180 mg m-2) + 5FU/LV OR FUIRI (weekly irinotecan 80 mg m-2) + 5FU/LV | - | Diarrhea | - | 58 | 216 | 0.27 | 32 | 93 | 0.344 | 90 | |||||||||||
Tuesday, March 26, 2013; Tuesday, August 9, 2016; Friday, June 22, 2018; Sunday, August 1, 2010; Wednesday, January 22, 2014; Wednesday, March 24, 2010; Saturday, February 25, 2017; Tuesday, August 5, 2008 |
PMID: 23529007; 27503581; 29932297; 20562211; 24448639; 20335017; 28367249; 18681783 | Thursday, May 17, 2007 | PMID: 17510208 | randomized, phase 3 trial | metastatic colorectal cancer patients | 184 | UGT1A1*1 | UGT1A1 -3156G>A polymorphism | LV5FU2 (leucovorin 200 mg/m2 as a 2-h infusion, 5FU 400 mg/m2 bolus and 600 mg/m2 22 h continuous infusion) to LV5FU2 + CPT-11 (LV5FU2 + irinotecan 180 mg/m2 90 min infusion) every 2 weeks for 12 cycles | Neutropenia (grade 3+) | - | - | 4 | 79 | 0.05 | 4 | 83 | 0.048 | 8 | ||||||||
Tuesday, March 26, 2013; Tuesday, August 9, 2016; Friday, June 22, 2018; Monday, November 16, 2020; Wednesday, June 13, 2012; Wednesday, February 12, 2014 |
PMID: 23529007; 27503581; 29932297; 24709690; 22676194; 24519753 | Tuesday, February 23, 2010 | PMID: 20177420 | multicenter, randomized, controlled trial | metastatic colorectal cancer patients | 140 | UGT1A1*1 | UGT1A1*28/*28, UGT1A1*1/*28 | no prior chemotherapy other than adjuvant 5FU based chemotherapy completed at least 6 months before the study. FLIRI (irinotecan 180 mg-2 as 60 min infusion day 1, 5FU 500 mg m-2 as bolus, FA 60 mg m-2 bolus) or LV5FU2-IRI (irinotecan 180 mg m-2 infusion, 5FU bolus 400 mg m-2 and FA 200 mg m-2 2 hr infusion, and 22 hr infusion of 5FU 600 mg m-2) | Neutropenia (grade 3-4) | Diarrhea (grade 3-4) | - | 15 | 72 | 0.21 | 20 | 64 | 0.3125 | 35 | no separation between the data in diarrhea and neutropenia toxicities, study grouped those together | |||||||
Friday, June 22, 2018; Wednesday, January 22, 2014; Friday, December 6, 2013; Wednesday, February 12, 2014; Saturday, Febraury 25, 2017; Monday, June 5, 2017 | PMID: 29932297; 24448639; 24308720; 24519753; 28367249; 28585035 | Friday, April 24, 2009 | PMID: 19390945 | prospective, randomized, controlled trial | Japanese cancer patients | 135 | SLCO1B1*1b, *5, and haplotype *15 | UGT1A1*6, *28, *60 | Irinotecan alone, irinotecan + platinum, irinotecan + other anticancer agents, FOLFIRI | Neutropenia (grade 3-4) | - | - | 0 | 41 | 0 | 1 | 62 | 0.02 | 1 | ||||||||
Tuesday, March 26, 2013; Friday, June 22, 2018; Monday, November 16, 2020; Wednesday, February 12, 2014 | PMID: 23529007; 29932297; 24709690; 24519753 | Wednesday, October 28, 2009 | PMID: 19859999 | multicenter, randomized, controlled trial | metastatic colorectal cancer patients | 105 | UGT1A1*6/*6 (wildtype) | UGT1A1*6/*7, UGT1A1 *7/*7 | FOLFIRI (irinotecan 80 mg/m2 iv over 30 mins, folinic acid 500 mg/m2 iv over 120 mins followed by 5FU 2000 mg/m2 iv over 24 hr weekly x6weeks) or modified IROX (oxaliplatin 85 mg/m2 iv over 120 min every 2 weeks and irinotecan 80 mg/m2 iv over 30 min weekly) | Neutropenic fever (grade 3-4) | - | - | 12 | 41 | 0.29 | 22 | 62 | 0.35 | 34 | ||||||||
PMID: 19859999 | multicenter, randomized, controlled trial | metastatic colorectal cancer | 105 | UGT1A1*6/*6 (wildtype) | UGT1A1*6/*7, UGT1A1 *7/*7 | FOLFIRI (irinotecan 80 mg/m2 iv over 30 mins, folinic acid 500 mg/m2 iv over 120 mins followed by 5FU 2000 mg/m2 iv over 24 hr weekly x6weeks) or modified IROX (oxaliplatin 85 mg/m2 iv over 120 min every 2 weeks and irinotecan 80 mg/m2 iv over 30 min weekly) | - | Diarrhea (grade 3-4) | - | 9 | 41 | 0.22 | 27 | 62 | 0.44 | 36 | |||||||||||
Tuesday, March 26, 2013; Tuesday, August 9, 2016; Friday, June 22, 2018; Sunday, August 1, 2010; Monday, November 16, 2020; Wednesday, September, 5, 2007; Wednesday, January 22, 2014; Wednesday, March 24, 2010; Saturday, February 25, 2017; Tuesday, August 5, 2008 |
PMID: 23529007; 27503581; 20562211; 24709690; 17728214; 24448639; 20335017; 28367249; 18681783 | Monday, August 16, 2004 | PMID: 15280927 | Cohort | metastatic colorectal cancer patients | 95 | UGT1A1*28 - *6/*6 | UGT1A1*28 - *6/*7 and *7/*7 | regimen A: irinotecan alone (350 mg m2 infused in 45 min iv q3weeks), regimen B: irinotecan + tomudex (3 mg m2 infused in 15 min iv), regimen C: irinotecan (80 mg m2 infused in 45 min iv every week) with a dose of 2250 mg m2 of 5FU in every cycle, and regimen D: irinotecan (180 mg m2 every 2 weeks iv) and 5FU + leucovorin iv. | Neutropenia (grade 3-4) | - | - | 6 | 40 | 0.15 | 16 | 55 | 0.3 | 22 | This study grouped heamatological toxicities together as (g3-4 neutropenia, anaemia, and thrombocytopenia) | 28 patients experienced more than 2 severe adverse effects at the same time. | ||||||
PMID: 15280927 | Cohort | metastatic colorectal cancer | 95 | UGT1A1*28 - *6/*6 | UGT1A1*28 - *6/*7 and *7/*7 | regimen A: irinotecan alone (350 mg m2 infused in 45 min iv q3weeks), regimen B: irinotecan + tomudex (3 mg m2 infused in 15 min iv), regimen C: irinotecan (80 mg m2 infused in 45 min iv every week) with a dose of 2250 mg m2 of 5FU in every cycle, and regimen D: irinotecan (180 mg m2 every 2 weeks iv) and 5FU + leucovorin iv. | - | Diarrhea (grade 3-4) | - | 7 | 40 | 0.175 | 22 | 55 | 0.4 | 29 | |||||||||||
Tuesday, March 26, 2013; Friday, June 22, 2018; Wednesday, September 5, 2007; Wednesday, March 24, 2010; Saturday, February 25, 2017; Tuesday, August 5, 2008 | PMID: 23529007; 29932297; 17728214; 20335017; 28367249; 18681783 | Sunday, August 1, 2004 | PMID: 15297419 | Retrospective Cohort | metastatic colorectal cancer patients | 75 | UGT1A1*6/*6 | UGT1A1*6/*7, UGT1A1 *7/*7 | IRIFUFOL regimen: irinotecan (85 mg/m2), 90 min weekly infusion + 5FU (1200 mg/m2) 7 hr weekly infusions and 100 mg/m2 bolus of L-folinic acid (28 patients). FOLFIRI regimen: 180 mg/m2 irinotecan biweekly infusion over 90 min + 2500 mg/m2 5FU, 46 hr continuous infusion and 400 mg/m2 bolus L-folinic acid (47 patients) | Neutropenia (grade 3-4) | - | - | 3 | 31 | 0.097 | 19 | 42 | 0.45 | 22 | ||||||||
- | Diarrhea | - | 1 | 31 | 0.032 | 4 | 42 | 0.095 | 5 | ||||||||||||||||||
Tuesday, August 9, 2016; Wednesday, January 22, 2014; Wednesday, March 24, 2010; Saturday, February 25, 2017 | PMID: 27503581; 24448639; 20335017; 28367249 | Tuesday, September 16, 2008 | PMID: 18797458 | clinical trial | metastatic colorectal cancer patients | 49 | UGT1A1*28 wildtype | UGT1A1*28 heterozygous and homozygous | FOLFIRI regimen: folinic acid 400 mg m-2 as a 2 hr IV infusion; 5FU 400 mg m-2 IV bolus, then 2400 mg m-2 as IV infusion over 46 hrs and irinotecan 180 mg m-2 as a 1.5 hr infusion q 2 weeks | Neutropenia | - | - | 3 | 23 | 0.13 | 9 | 21 | 0.43 | 12 | ||||||||
- | Diarrhea | - | 4 | 23 | 0.17 | 4 | 21 | 0.19 | 8 | ||||||||||||||||||
Tuesday, March 26, 2013; Friday, June 22, 2018; Monday, November 16, 2020; Wednesday, June 13, 2012; Saturday, February 25, 2017 | PMID: 2359007; 29932297; 24709690; 22676194; 28367249 | Saturday, July 10, 2010 | PMID: 20530282 | clinical trial | metastatic colorectal cancer patients | 520 | UGT1A1*28 (6/6) | UGT1A1*28 (6/7, 7/7) | IFL (Fluorouracil + Irinotecan), FOLFOX (FU + oxaliplatin) and IROX (IRN + oxaliplatin) | Neutropenia (grade >=4) | - | - | 34 | 230 | 0.15 | 57 | 267 | 0.21 | 91 | ||||||||
- | Diarrhea (grade >=3) | - | 43 | 230 | 0.19 | 50 | 267 | 0.19 | 93 | ||||||||||||||||||
not included in any | Thursday, October 29, 2020 | PMID: 33119477 | Multicenter, randomized, open-label prospective, phase III Clinical Trial | advanced rectal cancer | 356 | UGT1A1*1/*1 | UGT1A1*1/*28 | pelvic radiation of 50 Gy/25 fractions with concurrent capecitabine, followed by oxaliplatin and capecitabine; or radiation with capecitabine combined with weekly irinotecan 80 mg/m2 for patients with UGT1A1*1/*1 or 65 mg/m2 for patients with UGT1A1*1/*28 followed by irinotecan and capecitabine. | Neutropenia (grade 3-4) | - | 266 | - | - | 90 | - | 38 | |||||||||||
- | Diarrhea (grade 3-4) | - | - | 266 | - | - | 90 | - | 27 | ||||||||||||||||||
not included in any | Wednesday, January 5, 2022 | PMID: 34998046 | prospective, multicenter, non-randomized study | pathological malignancy | 350 | UGT1A1 poor metabolizers (homozygous for UGT1A1*28/*28 and *93/*93) | UGT1A1 non-poor metabolizers (heterozygous for UGT1A1*28 and/or UGT1A1*93 and UGT1A1 wild type) | irinotecan >=180 mg/m2 or 450-600 mg dose. PMs were given 30% dose reduction. | Neutropenia (grade 3-4) | - | - | 16 | 31 | 0.52 | 81 | 319 | 0.25 | 97 | |||||||||
- | Diarrhea (grade >=3) | - | 3 | 31 | 0.097 | 51 | 319 | 0.16 | 54 | ||||||||||||||||||
not included in any | Thursday, September 26, 2019 | PMID: 31558477 | Multicenter prospective | advanced gastrointestinal cancers | 50 | UGT1A1*1/*1 | UGT1A1*1/*28, UGT1A1*28/*28 | FOLFIRABRAX + prophylactic pegfilgrastim q14d. UGT1A1 *1/*1, *1/*28, *28/*28 Irinotecan doses of 180, 135, and 90 mg/m2 respectively. | Febrile neutropenia (grade 3) | - | - | 1 | 23 | 0.04 | 0 | 26 | 0 | 1 | |||||||||
- | Diarrhea (grade 3) | - | 3 | 23 | 0.13 | 0 | 26 | 0 | 3 | ||||||||||||||||||
not included in any | Monday, April 12, 2021 | PMID: 33728696 | prospective , observational cohort | small lung cancer | 213 | UGT1A1*28 homozygous wild, UGT1A1*6 homozygous wild | UGT1A1*28 homo/heterozygous mutant, UGT1A1*6 homo/heterozygous mutant | irinotecan 100 mg/m2 + cisplatin 60 mg/m2 each on day 1 of a 3 week cycle. An alternate regimen was irinotecan 65 mg.m2 + cisplatin 30 mg/m2 each on days 1 and 8 of a 3 week cycle. | Neutropenia (grade >= 3) | - | - | 19 | 141 | 0.135 | 13 | 72 | 0.18 | 32 | |||||||||
- | Diarrhea (grade >=3) | - | 23 | 141 | 0.16 | 22 | 72 | 0.31 | 45 | ||||||||||||||||||
not included in any | Wednesday, January 2, 2019 | PMID: 30603911 | retrospective analysis | advanced gastric cancer | 74 | UGT1A1*28/UGT1A1*6 (WT) | UGT1A1*6 G/G and *28 6/7, or *6 G/A and *28 6/6 SH (single heterozygous), homozygous/double heterozygosity with *6 A/A and *28 6/6 (homo for *6), *6 G/G and *28 7/7 (homo for *28) or UGT1A1*6 G/A and *28 6/7 (DH) | third line chemotherapy with irinotecan 150 mg/m2 q2weeks | Neutropenia (grade 3) | - | - | 5 | 37 | 0.14 | 9 | 37 | 0.24 | 14 | |||||||||
- | Diarrhea (grade 3) | - | 3 | 37 | 0.08 | 2 | 37 | 0.05 | 5 | ||||||||||||||||||
not included in any | Friday, July 24, 2020 | PMID: 32666389 | restrospectively reviewed clinical data | advanced gastric cancer | 100 | UGT1A1 WT | UGT1A1 SH (*6 for sure, possibly *28) | irinotecan 150 mg/m2 within 120 mins q2weeks | Neutropenia (grade >=3) | - | - | 9 | 62 | 0.15 | 12 | 38 | 0.32 | 21 | |||||||||
- | Diarrhea (grade >=3) | - | 2 | 62 | 0.03 | 1 | 38 | 0.03 | 3 | ||||||||||||||||||
not included in any | Thursday, August 20, 2020 | PMID: 32829105 | randomized, controlled trial | metastatic colorectal cancer patients | 107 | UGT1A1*6/*6 | UGT1A1*6/*7, UGT1A1*7/*7 | Biweekly FOLFIRI + bevacizumab | Neutropenia (grade 3-4) | - | - | - | 82 | - | - | 25 | - | 8 | |||||||||
- | Diarrhea (grade 3-4) | - | - | 82 | - | - | 25 | - | 4 | ||||||||||||||||||
not included in any | Wednesday, August 5, 2020 | PMID: 32758288 | Retrospective study | cervical cancer | 51 | UGT1A1 WT (*1/*1) | UGT1A1 HT/HZ (*1/*6, *1/*28, *6/*6, *28/*28) | Irinotecan as neoadjuvant and/or adjuvant treatment | Neutropenia (grade 3-4) | - | - | 7 | 24 | 0.29 | 15 | 27 | 0.55 | 22 | |||||||||
- | Diarrhea (grade > 3) | - | 4 | 24 | 0.166 | 3 | 27 | 0.11 | 7 | ||||||||||||||||||
not included in any | Monday, October 22, 2018 | PMID: 30246377 | clinical trial | locally advanced lower rectal cancer | 46 | UGT1A1*1/*1 (WT) | UGT1A1 Heterozygous (*28/*1, *6/*1) and homozygous (*28/*28, *6/*6, *28/*28), double heterozygous (*28/*6) | 80 mg/m2 per day tegafur/gimeracil/oteracil (S‐1; days 1‐5, 8‐12, 22‐26, and 29‐33), 60 mg/m2 per day irinotecan (days 1, 8, 22, and 29), and 45 Gy radiation (1.8 Gy/day, 5 days per week for 5 weeks). | Neutropenia (grade 3-4) | - | - | 0 | 26 | 0 | 8 | 20 | 0.4 | 8 | |||||||||
- | Diarrhea (grade 3-4) | - | 9 | 26 | 0.35 | 6 | 20 | 0.3 | 15 | ||||||||||||||||||
Wednesday, February 12, 2014; Saturday, February 25, 2017; Wednesday, September 5, 2007; Wednesday, March 24, 2010; Wednesday, July 28, 2010; Tuesday, April 04, 2014; Friday, June 22, 2018 | PMID: 24519753; 28367249; 17728214; 20335017; 20562211; 24709690; 29932297 | Wednesday, April 14, 2004 | PMID: 15007088 | clinical trial | histologically confirmed solid tumor or lymphoma | 66 | UGT1A1 6/6 | UGT1A1 6/7, 7/7 | Irinotecan 350 mg/m2 q3weeks | Neutropenia (grade 3-4) | - | - | 0 | 29 | 0 | 6 | 31 | 0.19 | 6 | ||||||||
Saturday, February 25, 2017; Tuesday, August 5, 2008; Wednesday, September 5, 2007; Wednesday, March 24, 2010; Wednesday, July 28, 2010; Thursday, June 7, 2012; Tuesday, March 26, 2013; Wednesday, January 22, 2014; Tuesday, April 4, 2014; Tuesday, August 9, 2016; Friday, June 22, 2018 | PMID: 28367249; 18681783; 17728214; 20335017; 20562211; 22676194; 23529007; 24448639; 24709690; 27503581; 29932297 | Saturday, July 1, 2006 | PMID: 16809730 | prospective interinstitutional study | metastatic colorectal cancer | 250 | UGT1A1 WT (TA6/TA6) | UGT1A1*28 (TA7/TA7, TA6/TA7) | modified FOLFIRI regimen (irinotecan 180 mg/m2, + FU 400 mg/m2 bolus dollowed by FU 600 mg/m2 continuous infusion + LV 200 mg/m2) | Neutropenia (grade 3-4) | - | - | 11 | 114 | 0.096 | 24 | 136 | 0.18 | 35 | ||||||||
- | Diarrhea (grade 3) | - | 6 | 114 | 0.05 | 15 | 136 | 0.11 | 21 | ||||||||||||||||||
Saturday, February 25, 2017; Tuesday, March 26, 2013; Tuesday, August 9, 2016; Friday, June 22, 2018 | PMID: 28367249; 23529007; 27503581; 29932297 | Thursday, April 26, 2012 | PMID: 22535333 | retrospective chart review | metastatic colorectal cancer | 101 | UGT1A1*1/*1, *1/*28, *28/*28 | UGT1A1 (*60, *93) | 5FU/Irinotecan based chemotherapy (Irinotecan 180 mg/m2) q2weeks, (Irinotecan (180 mg/m2) IV 2h infusion concurrent with leucovorin (200 mg/m2) followed by 5-FU (400 mg/m2) IV bolus followed by 5FU (2400 mg/m2) as a continuous 46 h infusion q 2weeks.) | Neutropenia (grade 3-4) | - | - | 18 | 59 | 0.31 | 38 | 42 | 0.9 | 56 | ||||||||
- | Diarrhea (grade 3-4) | - | 12 | 59 | 0.2 | 24 | 42 | 0.57 | 36 | ||||||||||||||||||
Wednesday, February 12, 2014; Saturday, February 25, 2017; Tuesday, March 26, 2013; Tuesday, April 4, 2014; Friday, June 22, 2018 | PMID: 24519753; 28367249; 23529007; 24709690; 29932297 | Tuesday, February 1, 2011 | PMID: 21287524 | population based case-control study | metastatic colorectal cancer | 214 | UGT1A1*28 (*6/*6) | UGT1A1*28 (*6/*7, *7/*7) | FOLFIRI, IFL, TEGAFIRI, XELIRI | Neutropenia (grade 3-4) | - | - | 5 | 91 | 0.05 | 14 | 123 | 0.11 | 19 | ||||||||
- | Diarrhea (grade 3-4) | - | 25 | 91 | 0.27 | 23 | 123 | 0.19 | 48 | ||||||||||||||||||
Tuesday, March 26, 2013 | PMID: 23529007 | Wednesday, February 9, 2011 | PMID: 21310730 | controlled trial | advanced colorectal cancer | 87 | UGT1A1*1/*1, *1/*28 or *1/*6 | UGT1A1*28/*28, *6/*6, *28/*6, or *28/*27 | : FOLFOX ( 2-h intravenous infusion of oxaliplatin (85 mg/m2) and LV (200 mg/m2), followed by an intravenous bolus injection of 5-FU (400 mg/m2) and a 46-h intravenous infusion of 5-FU (2400 mg/m2), repeated every 2 weeks.) OR FOLFIRI (2-h intravenous infusion of irinotecan (150 or 180 mg/m2) and LV (200 mg/m2) on Day 1, followed by an intravenous bolus injection of 5-FU (400 mg/m2) and a 46-h intravenous infusion of 5-FU (2400 mg/m2), repeated every 2 weeks.) | Neutropenia (grade 3-4) | - | - | 29 | 81 | 0.36 | 0 | 6 | 0 | 29 | ||||||||
- | Diarrhea (grade 3-4) | - | 2 | 81 | 0.025 | 0 | 6 | 0 | 2 | ||||||||||||||||||
Saturday, February 25, 2017; Wednesday, March 24, 2010; Tuesday, March 26, 2013 | PMID: 28367249; 20335017; 23529007 | Friday, September 8, 2006 | PMID: 16951398 | multicenter, double-blind, randomized, placebo-controlled trial | metastatic colorectal cancer | 62 | UGT1A1 TA 6/TA6 | UGT1A1 TA7/TA6, TA7/TA7 (*28/*28) | Irinotecan (350 mg/m2 once every 3 weeks) combined with neomycin (660 mg three times daily for 3 consecutive days, starting 2 days before chemotherapy) or combined with placebo | Neutropenia (grade 3-4) | - | - | 6 | 26 | 0.23 | 6 | 26 | 0.23 | 12 | ||||||||
- | Diarrhea (grade 2-3) | - | 9 | 26 | 0.35 | 9 | 26 | 0.35 | 18 | ||||||||||||||||||
Wednesday, February 12, 2014; Saturday, February 25, 2017; Wednesday, March 24, 2010; Thursday, June 7, 2012; Tuesday, March 26, 2013; Tuesday, April 4, 2014 | PMID: 24519753; 28367249; 20335017; 22676194; 23529007; 24709690 | Monday, April 21, 2008 | PMID: 18300238 | retrospective | metastatic colorectal cancer | 128 | UGT1A1 TA6/TA6 (WT) | UGT1A1 polymorphism (TA6/TA7 or TA7/TA7) | Irinotecan + 5-FU/Leucovorin | Neutropenia (grade 3-4) | - | - | 5 | 102 | 0.05 | 14 | 26 | 0.54 | 19 | ||||||||
- | Diarrhea (grade 3-4) | - | 6 | 102 | 0.06 | 7 | 26 | 0.27 | 13 | ||||||||||||||||||
Friday, June 22, 2018 | PMID: 29932297 | Sunday, December 6, 2015 | PMID: 26494856 | open-label, non-randomized, phase II trial | metastatic colorectal cancer | 86 | UGT1A1*1/*1 | UGT1A1*1/*28 | bevacizumab 5 mg/kg D1, irinotecan 260 mg/m2 D1, LV 400 mg/m2 D1, 5FU 400 mg/m2 IV bolus D1, and 5FU 2,400 mg/m2 46-hour infusion D1-2 every 2 weeks. | Neutropenia (grade 3-4) | - | - | 10 | 40 | 0.25 | 14 | 46 | 0.3 | 24 | ||||||||
- | Diarrhea (grade 3-4) | - | 7 | 40 | 0.175 | 4 | 46 | 0.09 | 11 | ||||||||||||||||||
Wednesday, October 21, 2020; Saturday, February 25, 2017; Monday, June 5, 2017; Friday, June 22, 2018 | PMID: 32936306; 28367249; 28585035; 29932297 | Tuesday, May 24, 2016 | PMID: 27220761 | retrospective analysis | advanced colorectal cancer | 183 | UGT1A1*6 | UGT1A1*28 (*1/*1, *1/*28, *28/*28) | FOLFIRI: first day, intravenous (iv) injection with irinotecan 150 mg/m2; first and second day, iv injection with tetrahydrofolic acid (THFC) 200 mg/m2 and 5-FU 400 mg/m2, and afterward with a continuous infusion pump with 5-FU 1200 mg/m2 for 44 h; repeated every 2 weeks, four cycles of treatment. Combination of irinotecan and capecitabine: first day, iv drip with irinotecan 150 mg/m2 for 90 min; second to the fifteenth day, iv drip with capecitabine 1000 mg/m2 (twice a day); repeated every 3 weeks. | Neutropenia (grade 3-4) | - | - | 14 | 114 | 0.12 | 14 | 114 | 0.12 | 28 | ||||||||
- | Diarrhea (grade 3-4) | - | 27 | 114 | 0.24 | 27 | 114 | 0.24 | 54 | ||||||||||||||||||
Friday, December 6, 2013; Wednesday, February 12, 2014; Saturday, February 25, 2017; Monday, June 5, 2017; Wednesday, March 24, 2010; Thursday, June 7, 2012; Wednesday, January 22, 2014; Tuesday, April 4, 2014; Friday, June 22, 2018 | PMID: 24308720; 24519753; 28367249; 28585035; 20335017; 22676194; 24448639; 24709690; 29932297 | Monday, April 24, 2006 | PMID: 16636344 | phase II study | NSCLC | 81 | UGT1A1*6/*6, UGT1A7*3/*3 | UGT1A9-118 | irinotecan 80 mg/m2 + cisplatin 60 mg/m2 | Neutropenia (grade 4) | - | - | 10 | 12 | 0.83 | 5 | 21 | 0.24 | 15 | ||||||||
- | Diarrhea (grade 3) | - | 4 | 12 | 0.33 | 5 | 21 | 0.24 | 9 | ||||||||||||||||||
Friday, December 6, 2013; Wednesday, February 12, 2014; Saturday, February 25, 2017; Monday, June 5, 2017; Wednesday, January 22, 2014; Tuesday, August 9, 2016; Friday, June 22, 2018 | PMID: 24308720; 24519753; 28367249; 28585035; 24448639; 27503581; 29932297 | Friday, December 7, 2012 | PMID: 23236239 | clinical trial | metastatic colorectal cancer | 138 | UGT1A1*6 (G/G, G/A, A/A) | UGT1A1*28 (TA 6/6, TA 6/7, TA 7/7) | FOLFIRI AND IFL, FOLFIRI: irinotecan 180 mg/m2 90-min i.v. infusion on day 1; leucovorin 200 mg/m2 i.v. infusion on days 1 and 2; followed on days 1 and 2 by 5-FU 400 mg/m2 i.v. bolus, then 600 mg/m2 i.v. over 22 h continuous infusion; repeated every 2 wk; (2) IFL: irinotecan 125 mg/m2 as a 90-min i.v. infusion on days 1, 8, 15 and 22; leucovorin 20 mg/m2 i.v. infusion on days 1, 8, 15 and 22; 5-FU 500 mg/m2 i.v. bolus on days 1, 8, 15 and 22; every 6 wk. | Neutropenia (grade 3-4) | - | - | 38 | 130 | 0.29 | 38 | 130 | 0.29 | 76 | ||||||||
- | Diarrhea (grade 3-4) | - | 23 | 130 | 0.178 | 23 | 130 | 0.178 | 46 | ||||||||||||||||||
Saturday, February 25, 2017; Wednesday, September 5, 2007; Wednesday, March 24, 2010; Wednesday, July 28, 2010 | PMID: 28367249; 17728214; 20335017; 20562211 | Thursday, March 14, 2002 | PMID: 11990381 | phase I clinical trial | solid tumors | 20 | *6/*6 | *6/*7, *7/*7 | Irinotecan 300 mg/m2 q3weeks | Neutropenia (grade 3-4) | - | - | 0 | 9 | 0 | 3 | 11 | 0.27 | 3 | ||||||||
- | Diarrhea (grade 3-4) | - | 0 | 9 | 0 | 2 | 11 | 0.2 | 2 | ||||||||||||||||||
Friday, December 6, 2013; Wednesday, February 12, 2014; Monday, June 5, 2017; Wednesday, January 22, 2014; Tuesday, August 9, 2016; Friday, June 22, 2018 | PMID: 24308720; 24519753; 28585035; 24448639; 27503581; 29932297 | Saturday, July 9, 2011 | PMID: 21740478 | clinical trial | metastatic gastronitestinal cancer | 82 | UGT1A1*1/*1 | UGT1A1*28/*1, *6/*1, *28/*28, *6/*6, *28/*6 | Irinotecan 150 mg/m2 | Neutropenia (grade 3-4) | - | - | 9 | 41 | 0.22 | 17 | 41 | 0.4 | 26 | ||||||||
- | Diarrhea (grade 3-4) | - | 0 | 41 | 0 | 1 | 41 | 0.02 | 1 | ||||||||||||||||||
Wednesday, February 12 2014; Wednesday, September 5, 2007; Wednesday, July 28, 2010; Wednesday, January 22, 2014 | PMID: 24519753; 17728214; 20562211; 24448639 | Friday, December 15, 2000 | PMID: 11156391 | case control study | cancer patients | 118 | UGT1A1*6 | UGT1A1*28 | irinotecan containing chemotherapy | Neutropenia (grade 3-4) | - | - | - | - | - | - | - | - | - | ||||||||
- | Diarrhea (grade 3-4) | - | 26 | 118 | 0.22 | 26 | 118 | 0.22 | 52 | ||||||||||||||||||
Saturday, February 25, 2017; Wednesday, March 24, 2010; Wednesday, July 28, 2010; Thursday, June 7, 2012; Tuesday, March 26, 2013; Tuesday, April 4, 2014; Friday, June 22, 2018 | PMID: 28367249; 20335017; 20562211; 22676194; 23529007; 24709690; 29932297 | Tuesday, July 1, 2008 | PMID: 18594531 | multicenter, phase III trial | metastatic colorectal cancer | 218 | UGT1A1*28 TA6/TA6 | UGT1A1*28 TA6/TA7, TA7/TA7 genotype | IRI OR CAPIRI regimen A: first-line capecitabine (1250 mg m−2 day−1 b.i.d. on days 1–14, every 3 weeks), second-line IRI (350 mg m−2 day−1 on day 1, every 3 weeks) and third-line capecitabine plus oxaliplatin. Regimen B: first-line capecitabine (1000 mg m−2 day−1 b.i.d. on days 1–14, every 3 weeks) plus IRI (250 mg −2 day−1 on day 1, every 3 weeks: capecitabine plus IRI (CAPIRI), followed by second-line capecitabine plus oxaliplatin. | Neutropenia (grade 3-4) | - | - | 2 | 105 | 0.02 | 12 | 99 | 0.12 | 14 | ||||||||
- | Diarrhea (grade 3-4) | - | 21 | 105 | 0.2 | 27 | 99 | 0.27 | 48 | ||||||||||||||||||
Friday, December 6, 2013; Wednesday, October 21, 2020; Wednesday, February 12, 2014; Saturday, February 25, 2017; Tuesday, March 26, 2013; Wednesday, January 22, 2014; Friday, June 22, 2018 | PMID: 24308720; 32936306; 24519753; 28367249; 28585035; 23529007; 24448639; 29932297 | Monday, February 7, 2011 | PMID: 21303789 | prospective phase II study | metastatic colorectal cancer | 52 | UGT1A1*6 | UGT1A1*28 | FOLFIRI (irinotecan 150 mg/m2) | Neutropenia (grade 3-4) | - | - | 17 | 39 | 0.44 | 17 | 39 | 0.44 | 34 | ||||||||
Saturday, February 25, 2017; Wednesday, March 24, 2010; Wednesday, January 22, 2014; Friday, June 22, 2018 | PMID: 28367249; 20335017; 24448639; 29932297 | Wednesday, July 11, 2007 | PMID: 17627617 | clinical trial | asian cancer patients | 45 | UGT1A1*6 | UGT1A1*28 | irinotecan 375 mg/m2 q3weeks | Neutropenia (grade 3-4) | - | - | 16 | 45 | 0.36 | - | - | - | 16 | ||||||||
- | Diarrhea (grade 3-4) | - | 6 | 45 | 0.13 | - | - | - | 6 | ||||||||||||||||||
Friday, December 6, 2013; Wednesday, February 12, 2014; Monday, June 5, 2017; Tuesday, March 26, 2013; Wednesday, January 22, 2014 | PMID: 24308720; 24519753; 28585035; 23529007; 24448639 | Tuesday, October 19, 2010 | PMID: 20957480 | retrospective study | advanced colorectal cancer | 42 | UGT1A1*1/*1 | UGT1A1*1/*6, *1/*28 | Irinotecan 180 mg/m2 + 5-FU 400 mg/m2 bolus, 46 hr infusion of 2400 mg/m2 + Leucovorin 200 mg/m2 q2weeks (FOLFIRI) | Neutropenia (grade 3-4) | - | - | 8 | 24 | 0.33 | 6 | 18 | 0.33 | 14 | ||||||||
- | Diarrhea (grade 3-4) | - | 0 | 24 | 0 | 1 | 18 | 0.05 | 1 | ||||||||||||||||||
not included in any | Monday, February 28, 2022 | PMID: 35267552 | Retrospective | pancreatic cancer | 154 | UGT1A1*1/*28, UGT1A1*1/*6 | UGT1A1*28/*28, UGT1A1*6/*6, UGT1A1*6/*28 | FOLFIRINOX, oxaliplatin (85 mg/m2) as a 2-h intravenous infusion (IVF), followed by leucovorin (400 mg/m2) administered as a 2-h IVF, and after 30 min, the addition of irinotecan (180 mg/m2) given as 90-min IVF, immediately followed by a 5-FU 400 mg/m2 bolus and 2400 mg/m2 IVF for 46 h, every 2 weeks. | Neutropenia (grade 3-4) | - | - | 42 | 66 | 0.64 | 14 | 17 | 0.82 | 59 | |||||||||
- | Diarrhea (grade 3-4) | - | 5 | 66 | 0.076 | 1 | 17 | 0.06 | 6 |